血管活性肠肽瘤

Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998;17:389-400.

• 摘要

Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93.

• 摘要

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13.

• 摘要

1.  Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998;17:389-400.

• 摘要

2.  Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii124-30.

• 全文
• 摘要

3.  Friesen S. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987 Apr;67(2):379-93.

• 摘要

4.  Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93.

• 摘要

5.  Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery. 1998 Dec;124(6):1050-5.

• 摘要

6.  Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004 Jan;28(1):93-7.

• 摘要

7.  Nikou GC, Toubanankis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005 Jul-Aug;52(64):1259-65.

• 摘要

8.  Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec;14(12):3492-500.

• 全文
• 摘要

9.  Holst JJ, Fahrenkrug J, Knuhtsen S, et al. Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in the control of fluid and bicarbonate secretion. Regul Pept. 1984;8:245-259.

• 摘要

10.  Robberecht P, Conlon TP, Gardner JD. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig: structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. J Biol Chem. 1976;251:4635-4639.

• 摘要

11.  Barbezat GO, Grossman MI. Intestinal secretion: stimulation by peptides. Science. 1971;174:422-424.

• 摘要

12.  Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol. 1993;72:354-363.

• 摘要

13.  Biancani P, Walsh JH, Behar J. Vasoactive intestinal polypeptide: a neurotransmitter for lower esophageal sphincter relaxation. J Clin Invest. 1984;73:963-967.

• 全文
• 摘要

14.  Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 1994;135:2662-2680.

• 摘要

15.  Doherty GM. Rare endocrine tumours of the GI tract. Best Prac Res Clin Gastroenterol. 2005 Oct;19(5):807-17.

• 摘要

16.  Rood RP, DeLellis RA, Dayal Y, et al. Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. Gastroenterology. 1988 Mar;94(3):813-8.

• 摘要

17.  Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016 Feb 20;34(6):588-96.

• 全文
• 摘要

18.  Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88.

• 全文
• 摘要

19.  Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S111-4.

• 摘要

20.  Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34(3 suppl):28-39S.

• 摘要

21.  Delaunoit T, Neczyporenko F, Rubin J, et al. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008 Feb;103(2):475-83.

• 摘要

22.  Nguyen HN, Backes B, Lammert F, et al. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci. 1999 Jun;44(6):1148-55.

• 摘要

23.  Thompson LA, Kim M, Wenger SD, et al. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. Ann Pharmacother. 2012 Sep;46(9):1212-9.

• 摘要

24.  Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13.

• 摘要

25.  National Institute for Health and Care Excellence. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease. June 2017 [internet publication].

• 全文

26.  Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007 May;188(5):1201-7.

• 全文
• 摘要

27.  King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008 Sep 1;113(5):921-9.

• 摘要

28.  Johnston PC, Ardill JE, Johnston BT, et al. Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation. Ir J Med Sci. 2010 Sep;179(3):439-41.

• 摘要

29.  Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation. 2011 Mar 15;91(5):575-82.

• 摘要

30.  Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008 Jun;23(3):292-300.

• 摘要